Top

Published in:

07-03-2024 | Obesity | Research

Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study

Authors: Eirini Kostopoulou, Dimitra Kalavrizioti, Panagiota Davoulou, Xenophon Sinopidis, Evangelos Papachristou, Dimitrios S. Goumenos, Gabriel Dimitriou, Bessie E. Spiliotis, Marios Papasotiriou

Published in: European Journal of Pediatrics | Issue 5/2024

Abstract

Pediatric obesity and type 1 diabetes mellitus (T1DM) represent two common chronic diseases associated with chronic inflammation, endothelial dysfunction and long-term complications. The aim of the present study was to assess the possible diagnostic and prognostic value of soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammation and impaired endothelial function, in children with the diseases. In this cross-sectional study, children and adolescents with T1DM (N = 41) or obesity (N = 37), aged < 18 years old, and without proteinuria were included, together with children of similar age and without evident morbidity that served as controls (N = 42). Serum samples were obtained during standard outpatient follow up and the urokinase-type plasminogen activator receptor (suPAR) concentrations were measured using a commercially available sandwich ELISA kit (DUP00, R&D systems). Clinical and biochemical indices that were also assessed include body mass index (BMI) z-score, Tanner stages, glycosylated haemoglobin (HbA1c), fasting lipid profile and serum creatinine. Mean serum suPAR levels were significantly higher in patients with obesity compared to patients with T1DM and controls, while children with T1DM had similar suPAR levels to controls. Also, serum suPAR levels showed a negative correlation with age (Spearman rho −0.359, p < 0.001) and serum creatinine levels (Spearman rho −0.334, p = 0.005), and a positive correlation with BMI z-score (Spearman rho 0.354, p = 0.009) in the whole cohort.

Conclusion: Serum suPAR may be a useful predictive marker of inflammation or endothelial dysfunction for children with obesity and T1DM, as well as a promising therapeutic target. Further studies are needed in order to clarify whether the reported differences in suPAR levels could reflect a greater impairment of the inflammation status and endothelial function in children with obesity compared to children with T1DM.

What is Known:

• Paediatric obesity and type 1 diabetes are characterised by chronic inflammation and metabolic dysregulation.

• Urokinase plasminogen activator receptor (uPAR) has been proposed as a useful biomarker for chronic inflammation and cardiovascular risk in adults.

What is New:

• Serum suPAR levels were increased in children and adolescents with obesity compared to those with T1DM and healthy controls; thus, obesity may affect the inflammatory status and endothelial function to a higher degree than T1DM during childhood.

• Serum suPAR may serve as a diagnostic and predictive marker of inflammation and endothelial dysfunction for children and adolescents with obesity and T1DM.

Available only for authorised users

Di Cesare M, Sorić M, Bovet P et al (2019) The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med 17:1–20. https://doi.org/10.1186/S12916-019-1449-8CrossRef

Guo SS, Wu W, Chumlea WC, Roche AF (2002) Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am J Clin Nutr 76:653–658. https://doi.org/10.1093/AJCN/76.3.653CrossRefPubMed

Freedman DS, Dietz WH, Srinivasan SR, Berenson GS (2009) Risk factors and adult body mass index among overweight children: the Bogalusa Heart Study. Pediatrics 123:750–757. https://doi.org/10.1542/PEDS.2008-1284CrossRefPubMed

Es MU, Şenol S, Yüksel A, Kargün K (2016) OP-042 endothelin-1 gene polymorphisms in patients with peripheral artery disease. Am J Cardiol 117:S17. https://doi.org/10.1016/J.AMJCARD.2016.04.085CrossRef

Van der Schueren B, Ellis D, Faradji RN et al (2021) Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol 9:776–785. https://doi.org/10.1016/S2213-8587(21)00246-1CrossRefPubMed

Corbin KD, Driscoll KA, Pratley RE et al (2018) Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms. Endocr Rev 39:629–663. https://doi.org/10.1210/ER.2017-00191CrossRefPubMed

Klein R (1995) Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258–268. https://doi.org/10.2337/DIACARE.18.2.258CrossRefPubMed

De Ferranti S, Mozaffarian D (2008) The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 54:945–955. https://doi.org/10.1373/CLINCHEM.2007.100156CrossRefPubMed

Devaraj S, Cheung AT, Jialal I et al (2007) Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56:2790–2796. https://doi.org/10.2337/DB07-0784CrossRefPubMed

10.

Donadello K, Scolletta S, Covajes C, Vincent JL (2012) suPAR as a prognostic biomarker in sepsis. BMC Med 10:1–9. https://doi.org/10.1186/1741-7015-10-2CrossRef

11.

Heraclides A, Jensen TM, Rasmussen SS et al (2013) The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia 56:1542–1546. https://doi.org/10.1007/S00125-013-2914-0CrossRefPubMed

12.

Cancello R, Rouault C, Guilhem G et al (2011) Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects. Obes Facts 4:17–25. https://doi.org/10.1159/000324587CrossRefPubMedPubMedCentral

13.

Kosecik M, Dervisoglu P, Koroglu M et al (2017) Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children. Int J Cardiol 228:158–161. https://doi.org/10.1016/J.IJCARD.2016.11.201CrossRefPubMed

14.

Hodges GW, Bang CN, Wachtell K et al (2015) suPAR: a new biomarker for cardiovascular disease? Can J Cardiol 31:1293–1302. https://doi.org/10.1016/J.CJCA.2015.03.023CrossRefPubMed

15.

Wrotek A, Jackowska T (2015) The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia. Respir Physiol Neurobiol 209:120–123. https://doi.org/10.1016/J.RESP.2014.12.018CrossRefPubMed

16.

El-Mekkawy MS, Saleh NY, Sonbol AA (2016) Soluble urokinase plasminogen activator receptor: a new biomarker in the pediatric intensive care unit. Indian J Pediatr 83:661–669. https://doi.org/10.1007/S12098-016-2063-9CrossRefPubMed

17.

Cyrille N, Villablanca PA, Ramakrishna H (2016) Soluble urokinase plasminogen activation receptor–an emerging new biomarker of cardiovascular disease and critical illness. Ann Card Anaesth 19:214–216. https://doi.org/10.4103/0971-9784.179588CrossRefPubMedPubMedCentral

18.

Sołtysiak J, Zachwieja J, Benedyk A et al (2019) Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. Minerva Pediatr 71:4–11. https://doi.org/10.23736/S0026-4946.16.04461-3CrossRefPubMed

19.

Chiang JL, Maahs DM, Garvey KC et al (2018) Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care 41(9):2026–2044. https://doi.org/10.2337/dci18-0023CrossRefPubMedPubMedCentral

20.

Anderson LN, Carsley S, Lebovic G, Borkhoff CM, Maguire JL, Parkin PC, Birken CS (2017) Misclassification of child body mass index from cut-points defined by rounded percentiles instead of Z-scores. BMC Res Notes 10(1):639. https://doi.org/10.1186/s13104-017-2983-0CrossRefPubMedPubMedCentral

21.

Harding JL, Pavkov ME, Magliano DJ et al (2019) Global trends in diabetes complications: a review of current evidence. Diabetologia 62:3–16. https://doi.org/10.1007/S00125-018-4711-2CrossRefPubMed

22.

Haupt TH, Kallemose T, Ladelund S et al (2014) Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights 9:91–100. https://doi.org/10.4137/BMI.S19876CrossRefPubMedPubMedCentral

23.

Lyngbæk S, Marott JL, Sehestedt T et al (2013) Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk score. Int J Cardiol 167:2904–2911. https://doi.org/10.1016/J.IJCARD.2012.07.018CrossRefPubMed

24.

Rohde C, Polcwiartek C, Andersen E et al (2018) Effect of a physical activity intervention on suPAR levels: a randomized controlled trial. J Sci Med Sport 21:286–290. https://doi.org/10.1016/J.JSAMS.2017.06.018CrossRefPubMed

25.

Lyngbæk S, Sehestedt T, Marott JL et al (2013) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 167:781–785. https://doi.org/10.1016/J.IJCARD.2012.03.040CrossRefPubMed

26.

Hamie L, Daoud G, Nemer G et al (2018) SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgrad Med J 94:517–524. https://doi.org/10.1136/POSTGRADMEDJ-2018-135839CrossRefPubMed

27.

Van Der Backes Y, Mackie DP et al (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38:1418–1428. https://doi.org/10.1007/S00134-012-2613-1CrossRefPubMedPubMedCentral

28.

Edsfeldt A, Nitulescu M, Grufman H et al (2012) Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 43:3305–3312. https://doi.org/10.1161/STROKEAHA.112.664094CrossRefPubMed

29.

Eugen-Olsen J, Andersen O, Linneberg A et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296–308. https://doi.org/10.1111/J.1365-2796.2010.02252.XCrossRefPubMed

30.

Persson M, Engström G, Björkbacka H, Hedblad B (2012) Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Atherosclerosis 220:502–505. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2011.10.039CrossRefPubMed

31.

Rundgren M, Lyngbaek S, Fisker H, Friberg H (2015) The inflammatory marker suPAR after cardiac arrest. Ther Hypothermia Temp Manag 5:89–94. https://doi.org/10.1089/THER.2014.0027CrossRefPubMed

32.

Torino C, Pizzini P, Cutrupi S et al (2018) Soluble urokinase plasminogen activator receptor (suPAR) and all-cause and cardiovascular mortality in diverse hemodialysis patients. Kidney Int Rep 3:1100–1109. https://doi.org/10.1016/J.EKIR.2018.05.004CrossRefPubMedPubMedCentral

33.

Can U, Buyukinan M, Yerlikaya FH (2017) Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity. Indian J Med Res 145:327–333. https://doi.org/10.4103/IJMR.IJMR_1195_15CrossRefPubMedPubMedCentral

34.

Raff H, Phillips JM, Simpson PM et al (2020) Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity. Pain Rep 5(4):e836. https://doi.org/10.1097/PR9.0000000000000836CrossRefPubMedPubMedCentral

35.

Kayama Y, Raaz U, Jagger A et al (2015) Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci 16:25234. https://doi.org/10.3390/IJMS161025234CrossRefPubMedPubMedCentral

36.

Guo SM, Han M, Chen MX et al (2015) Soluble urokinase receptor levels are correlated with focal segmental glomerulosclerosis lesions in IgA nephropathy: a cohort study from China. PLoS ONE 10(9):e0138718. https://doi.org/10.1371/JOURNAL.PONE.0138718CrossRefPubMedPubMedCentral

37.

Zeier M, Reiser J (2017) suPAR and chronic kidney disease-a podocyte story. Pflugers Arch 469:1017–1020. https://doi.org/10.1007/S00424-017-2026-7CrossRefPubMed

38.

Zhou Y, Ren J, Li P et al (2019) Expression of urokinase-type plasminogen activator receptor and its soluble form in type 2 diabetic kidney disease. Arch Med Res 50:249–256. https://doi.org/10.1016/J.ARCMED.2019.08.007CrossRefPubMed

39.

Prevete N, Liotti F, Marone G et al (2015) Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacol Res 102:184–191. https://doi.org/10.1016/J.PHRS.2015.09.017CrossRefPubMed

40.

Dal Monte M, Cammalleri M, Pecci V et al (2019) Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. J Cell Mol Med 23:1034–1049. https://doi.org/10.1111/JCMM.14004CrossRefPubMed

41.

Theilade S, Lyngbæk S, Hansen TW et al (2015) Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med 277:362–371. https://doi.org/10.1111/JOIM.12269CrossRefPubMed

42.

Curovic VR, Theilade S, Winther SA et al (2019) Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes. Diabetes Care 42:1112–1119. https://doi.org/10.2337/DC18-1427CrossRef

43.

Sherif EM, El Maksood AAA, Youssef OI et al (2019) Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications. J Diabetes Complications 33:628–633. https://doi.org/10.1016/J.JDIACOMP.2019.06.001CrossRefPubMed

Title: Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study
Authors: Eirini Kostopoulou
Dimitra Kalavrizioti
Panagiota Davoulou
Xenophon Sinopidis
Evangelos Papachristou
Dimitrios S. Goumenos
Gabriel Dimitriou
Bessie E. Spiliotis
Marios Papasotiriou
Publication date: 07-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Obesity
Obesity
Urokinase
Type 1 Diabetes
Published in: European Journal of Pediatrics / Issue 5/2024
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-024-05496-5

At a glance: The STEP trials

Springer Medicine

Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Meeting the 24-h movement recommendations and its relationship with Mediterranean dietary patterns in early childhood: the SENDO project

Is adherence to the 24-h movement guidelines associated with greater academic-related outcomes in children and adolescents? A systematic review and meta-analysis

Gingival bleeding is a useful clinical feature in the diagnosis of hereditary bleeding disorders in children

Effect of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial

A significant increase in anthropometric indices during long-term follow-up of pediatric patients with celiac disease, with no endocrine disorders

Congenital diaphragmatic hernia: automatic lung and liver MRI segmentation with nnU-Net, reproducibility of pyradiomics features, and a machine learning application for the classification of liver herniation